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Abstract 
 
Introduction: Prescribing of medicines is a fundamental component of care for the elderly. 
However, increasing concern with polypharmacy and its impact on morbidity, mortality 
and costs. Aims: Analyze long-term prescription use and the prevalence of polypharmacy 
in the elderly in the Republic of Srpska. Subsequently use the findings to suggest potential 
future measures. Methods: Retrospective study of all elderly patients 2005 to 2010 
stratified by age group (3 groups), sex and long term medicine use. Results: Polypharmacy 
(5 or more medicines) increased from 1.4% of the elderly taking medicines long term to 
3.6% by 2010, with 53.6% of elderly taking 2 or more medicines long term. Most prevalent 
diseases were cardiovascular diseases and diabetes. Most prescriptions were in accordance 
with recent guidelines. However, concern with appreciable prescribing of digoxin and 
aminophylline. Conclusion: Whilst polypharmacy rates low in the Republic, increasing 
rates are a concern. Further studies are planned.  
 
Introduction     
 
The prescribing of medicines is a fundamental component of the care of the elderly, and 
optimizing drug prescribing for this group has become an important public health issue in 
recent years. This is due to the increasing prevalence of multiple medical conditions in the 
elderly leading to increasing rates of polypharmacy with its associated morbidity, mortality 
and costs  (1-6). However, the issue of multiple medications is complex. In some patients, 
polypharmacy is appropriate to slow disease progression or alleviate symptoms, especially 
in patients with multiple comorbidities (1, 2, 4). However in others, polypharmacy can 
cause serious problems for patients and healthcare systems (1, 3, 4, 7, 8). These include 
adverse drug reactions and potentially harmful drug - drug interactions, increased exposure 
to potentially inappropriate medicines, poor adherence, reducing the health benefits of 
prescribed medications as well as an increase in geriatric syndromes including urinary 
incontinence, cognitive impairment and impaired balance leading to increased falls (1, 7, 9-
17). As a result, polypharmacy can increase morbidity and mortality in the elderly, reducing 
their quality of life and increasing costs (1, 4, 7, 11, 12). For instance, the US Centre for 
Medicare and Medicaid services estimated that polypharmacy cost the US health plans 
more than US$50 billion annually at the end of the 1990s (4). Consequently, the leading 
challenge to the quality of medicine use in the elderly is to combine potential issues of 
polypharmacy, comorbidity and frailty with evidence and guidelines to avoid prescribing 
uncertainty of confusion, which may delay effective decision making regarding medicine 
use (18).  
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These factors, combined with aging populations worldwide, makes tackling inappropriate 
polypharmacy of the elderly of prime importance among all key stakeholder groups. These 
include health authorities looking to improve the care of the elderly within finite budgets 
(1, 2, 19-21). These concerns have resulted in a number of measures and interventions to 
reduce inappropriate prescribing, recently collated and updated in a Cochrane review (1, 
22) as well as discussed by Jäger and colleagues (17). Polypharmacy has been variously 
defined. A number of studies use a numeric definition, which is typically 5 or more 
medicines (1, 3, 16, 17, 21, 23-27). However, others have used a definition of 6 or more 
medicines (28, 29), whilst Patterson and colleagues and others use a definition of 4 or more 
medicines (1, 30, 31). Some authors have also used a definition as low as 2 or more 
medicines (27, 32).  
 
Polypharmacy is correlated with increasing age and the female gender (6, 33).  It has also 
been described, and is being addressed in several European and other countries (6, 8, 17, 
24, 25, 30, 34-39).  However, it is difficult to estimate the true prevalence of polypharmacy. 
Recent surveys suggest prevalence rates among the elderly of between 28% (US) and 31% 
(Ireland) (1). However, a recent survey in the Lombardia Region in Italy suggest higher 
prevalence rates, with those exposed to chronic polypharmacy (5 or different chronic drugs) 
at 28.5 % and rising to 52.7 % when considering the elderly prescribed 5 or more different 
active substances (34). These rates are likely to grow, especially with growing elderly 
populations as seen in Europe (31, 40, 41). This will lead to increased morbidity, mortality 
and costs among the elderly unless addressed (42).  These concerns have already resulted in 
a number of initiatives among healthcare professionals in the Balkan countries to improve 
the quality of prescribing in the elderly. These include the instigation of local 
pharmacotherapeutic groups with indicators for polypharmacy in Slovenia (20, 43, 44) and 
the development of new comprehensive screening tools to detect potentially inappropriate 
medications and clinically important drug-drug interactions in the elderly in Croatia (8). 
 
Bosnia and Herzegovina is no different with a growing elderly population as life 
expectancy increases. To the best of our knowledge, no analysis has been undertaken on the 
use of medicines in the elderly population in Bosnia and Herzegovina. Any increase in 
inappropriate polypharmacy is a particular issue in the Republic of Srpska, which is one of 
the two constitutive entities of Bosnia and Herzegovina with an estimated population of 1.4 
million, especially with yearly pharmaceutical expenditure at only ¼SHUFDSLWDLQ
(45).  
Primary health care in the Republic of Srpska is based on the family medicine concept 
represented by the family medicine team (46). Each team comprises one doctor, a family 
medicine specialist, and two nurses, and serves a defined and registered population. There 
are typically 2000 people per family medicine team. Service provision is driven by the 
contracts between the Health Insurance Fund (HIF) and primary health care providers, 
which define the scope of the services delivered and specify the use of evidence-based 
guidelines.  The first set of guidelines were developed and introduced in 2004, followed by 
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the second revised and improved edition in 2009. This set of guidelines with recommended 
treatments serves as a basis for the essential drug list for primary health reimbursed by the 
HIF of the Republic of Srpska. 
  
Consequently, the objective of this study was to analyze the long-term prescription drug use 
and the prevalence of polypharmacy in the elderly population in the Republic of Srpska. 
Subsequently use the findings to suggest, if pertinent, potential future measures that the 
Republic of Srpska could introduce to improve prescribing in the elderly. Potential 
measures will be based on published approaches including those in the recent Cochrane 
Review (1). 
 
Methods 
 
The Republic of Srpska has its own executive and legislative functional responsibilities 
including healthcare policies on its territory. The Health Insurance Fund (HIF) provides 
compulsory health insurance coverage for the entire population, meaning that all elderly are 
covered by a health insurance. The list of reimbursed drugs provided by HIF is based on 
Anatomical Therapeutic Chemical (ATC) classification (45, 46). 
 
This was a retrospective study, analysing DOOSUHVFULSWLRQVIRUSHRSOHDJHG\HDUV
reimbursed by HIF and dispensed by retail pharmacies during 2005 and 2010.  The HIF 
database provides the complete reimbursed prescription medication history of all patients, 
diagnoses, physician prescribers as well as the pharmacy where prescriptions are dispensed 
in the Republic of Srpska. The validity of the database is assured by regular monitoring and 
auditing of medicines dispensed from HIF contracted pharmacies, ensuring robustness of 
the findings. Data collection is unified and computerised, minimising the possibility of 
errors in data processing. Since all elderly, who are covered by HIF, were included in the 
study, problems concerning sampling, interviews and confidence were avoided.  
 
The following data sets were extracted from the database: dispensed drug, dispensing date, 
age, gender and disease diagnose (according to the WHO International Classification of 
Diseases [ICD] revision 10). All processing of the individual data of dispensed drugs in the 
study were undertaken anonymously, with a unique temporary individual identifier 
specifying gender and year of birth applied.  
 
The study population was stratified by gender and age into 10-year groups: 65-74 years, 75-
\HDUVDQG\HDUV7KHOLVWRIUHLPEXUVHGPHGLFLQHVcomprised 130 and 203 different 
medicines respectively in 2005 and 2010 by international non-proprietary name (INN - 
ATC level 5). This was a single list of medicines until 2008. After this, the list was divided 
into list A and list B. List A is the basic list of medicines including those for chronic 
diseases such as epilepsy, diabetes, cardiovascular diseases as well as chronic psychiatric 
conditions. Medicines are covered 100% up to the reference price level for patients exempt 
from the copayment.  List B is a complementary list with a mandatory 50% copayment, 
5 
 
5 
 
which typically includes second-line and/or more expensive treatments. Both lists A and B 
have prescribing indication limitations regarding reimbursement for certain medicines (45). 
For example, furosemide 500 mg tablets are included in list A with restricted prescribing, 
while furosemide 40 mg tablets are included within list B. In 2008 simvastatin and 
atorvastatin were switched to list B and restricted to specific diseases and conditions 
defined by ICD-10. These were secondary prevention of coronary disease (I20±I25), 
diabetes mellitus with hypercholesterolemia (E10±E11) and chronic kidney insufficiency 
(N18) and organ transplantation (Z24) with hypercholesterolemia 
 
Long-term medicine use was defined as continuous drug dispensing for a whole year or at 
least two thirds of the year (32), which implies medicines were used for the treatment of 
chronic diseases. Medicine use was assumed to start on the day the medication was 
dispensed. The number of different medicines prescribed was stratified into three groups: 
namely 1, 2-DQGPHGLFLQHV. Polypharmacy was defined as the use of five or more 
different reimbursed medicines - defined by the ATC-Code - during one year, which is in 
line with other publications (1, 3, 16, 17, 21, 23-27). The prevalence of medicine use was 
defined as the proportion of elderly patients who used 1, 2-DQGGLIIHUHQWreimbursed 
medicines during one year. This is similar to the methodology used by Franchi et al and 
Kennerfalk et al (34, 47).  
 
Descriptive analyses were conducted on the data to demonstrate possible increases or 
decreases in the number of patients in the different age groups as well as any changes in the 
prevalence of different diseases and different medicines prescribed over time. No statistical 
analyses were undertaken to analyze any significant increase or decrease in the number of 
patients among the different age groups and sexes in 2010 compared to 2005. This was 
because there was no intervention and no opportunity for re-accessing individual patient 
level data . All analyses were undertaken using Microsoft Excel 2010 programme. The 
results were presented in tables. 
 
Ethical approval was not needed since upon the review of the study protocol, which 
specified that all processing of individual patient data will be undertaken anonymously, 
with a unique temporary individual identifier, the study was approved by the Head of HIF. 
The data extraction was subsequently carried out within HIF with anonymous data, with 
patients fully de-identified. This is similar to other studies of this nature undertaken with 
health insurance company data, such as those conducted in the US (48). 
 
Results 
 
Table 1 describes the chDUDFWHULVWLFVRIWKH+,)SDWLHQWVDJHG\HDUV with long-term 
medicine use in the Republic of Srpska. Among the elderly, long-term medicine use was 
identified in 10% and 19% patients in 2005 and 2010, respectively. 
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Table 1. Characteristics of the study population 
 
Year 2005 2010 
Total elderly (number) 200,093 227,804 
Cohort (number of patients) 19,404 43,782 
Gender -  % Women 61.0 61.7 
Age  group (years), % of the total 
  
   65-74  69.2 59.9 
   75-84  29.0 36.5 
    1.8 3.6 
 
Of all the prescription medicines prescribed to the elderly, 29% (468,351) and 35% 
(954,135) were prescribed for long-term use in 2005 and 2010, respectively, and 60% of 
these were prescribed to women. 
  
One medicine alone was taken by almost 50% and 43% of the elderly in 2005 and 2010, 
respectively. There was generally greater use of medicines among men than women in 2005 
Table 2). However in 2010, there was generally greater use of medicines by women with 
the exception of those only prescribed one medicine (Table 2). The proportion of elderly 
who used one medicine only decreased in all age groups of both genders in 2010 versus 
2005 (Table 2).  
 
Table 2 ± Prevalence of the use of different medicines by age and gender from the cohort of 
patients prescribed medicines long term 
 
Year
Medicines - number    1    2-4     1    2-4 
Total (y) and % 49.8 48.8 1.4 42.9 53.6 3.6
   65-74 50.9 47.4 1.2 44.1 52.6 3.3
   75-84 47.4 50.8 1.9 41.3 54.8 3.9
 44.2 53.3 2.6 38.9 56.7 4.5
Men (y) and % 49.6 48.8 1.6 43.8 52.9 3.4
   65-74 50.5 48.1 1.4 44.2 52.6 3.2
   75-84 47.7 50.3 2.0 43.2 53.1 3.6
 45.5 50.9 3.6 40.7 55.2 4.1
Women (y) and % 49.9 48.8 1.3 42.3 54.0 3.7
   65-74 51.2 47.7 1.1 43.9 52.7 3.4
   75-84 47.2 51.1 1.8 40.1 55.8 4.1
 43.6 53.4 2.1 37.9 57.4 4.7
2005 2010
 
 
Two to four different medicines were taken by almost 49% and 54% of the elderly in 2005 
and 2010, respectively, and these were taken more by women than men. The proportion of 
patients who took 2-4 medicines increased in all age groups and for both genders in 2010 
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versus 2005, whilst those taking only one medicine decreased in both genders 2010 versus 
2005 (Table 2). 
 
In the total observed elderly population, polypharmacy prevalence using our definition also 
increased from 1.4% in 2005 to 3.6% in 2010. It increased in all age groups, with the 
largest increase seen in the age group 65-74 iQPHQDQGLQZRPHQ7DEOH). In men, 
polypharmacy prevalence increased from 1.6% to 3.4%, and in women from 1.3% in 2005 
to 3.7% in 2010 (Table 2).  
 
The most commonly used medicines were for the treatment of cardiovascular, metabolic, 
digestive and respiratory diseases (Table 3).  
 
Table 3 ± The most common diseases for which elderly patients were prescribed medicines 
(% of the total), ranked by 2010 figures 
 
Men
(n=7561)
Women
(n=11842)
Total
(n=19403)
Men
(n=16792)
Women
(n=26989)
Total
(n=43781)
I10 Hypertension 72.1 77.6 75.5 72.7 80.2 77.4
I20 Angina pectoris 34.7 31.5 32.7 24.0 22.7 23.2
I42 Cardiomiopathy 30.0 28.7 29.2 15.9 17.3 16.8
E11 Diabetes mellitus, type 2 10.9 13.3 12.4 14.3 17.0 16.0
E10 Diabetes mellitus, type 1 9.2 12.2 11.0 8.0 9.2 8.7
I50 Heart failure 2.3 2.3 2.3 8.5 9.0 8.8
K29 Gastritis and duodenitis 6.7 7.1 6.9 4.9 6.0 5.6
I25 Chronic ischaemic heart disease 6.9 5.7 6.2 6.0 5.1 5.5
I49 Cardiac arrhythmias 5.5 5.5 5.5 3.9 4.1 4.0
J42 Chronic bronchitis 11.2 6.1 8.1 5.8 3.7 4.5
J44 Other COPD 5.4 2.5 3.6 4.7 2.3 3.0
J45 Asthma 7.7 3.3 5.0 4.1 2.3 3.0
F32 Depressive episode 1.5 1.8 1.7 2.3 3.1 2.8
F20 Schizophrenia 2.5 2.8 2.7 1.1 1.3 1.2
F48 Other neurotic disorders 3.0 3.8 3.5 0.9 1.2 1.1
M54 Dorsalgia 2.2 2.9 2.6 0.6 0.9 0.8
 Disease (ICD-10) 
2005 2010
 
NB: ICD = International Classification of Diseases; COPD - Chronic Obstructive Pulmonary 
Disease 
 
Medicines for the treatment of hypertension, particularly angiotensin-converting enzyme 
inhibitors (ACEIs) and calcium channel blockers (CCB), and medicines for cardiac therapy 
(digoxin, isosorbide mononitrate) were the most frequently prescribed cardiovascular 
medicines (Table 4).  Medicines for diabetes and acid related disorders were the most 
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prescribed treatments for metabolic and digestive diseases, and aminophylline for 
obstructive airway diseases (Table 4). 
 
Table 4 - The most frequently prescribed drugs (% of the total number of patients), ranked 
by 2010 figures 
  
Men
(n=7561)
Women
(n=11842)
Total
(n=19403)
Men
(n=16792)
Women
(n=26989)
Total
(n=43781)
C09BA02 Enalapril and diuretics 4.6 5.7 5.3 18.1 22.5 20.8
C09AA02 Enalapril 13.5 14.6 14.2 18.0 18.2 18.1
C08CA01 Amlodipine 17.4 18.4 18.0 14.9 16.7 16.0
C01DA14 Isosorbide mononitrate 19.8 16.2 17.6 13.7 12.8 13.2
C01AA05 Digoxin 10.0 10.9 10.5 9.6 10.6 10.3
A10BA01 Metformin 3.3 4.7 4.1 8.0 10.1 9.3
C09BA06 Quinapril and diuretics 1.9 2.8 2.4 5.4 7.3 6.6
C07AG02 Carvedilol 3.6 2.3 2.8 6.4 6.6 6.5
C07AB02 Metoprolol na na na 4.9 6.7 6.0
A02BA02 Ranitidine 7.2 7.8 7.5 4.6 5.4 5.1
C08DA01 Verapamil 5.5 6.2 5.9 4.3 5.3 4.9
R03DA05 Aminophylline 9.1 4.4 6.2 6.1 3.4 4.4
C03CA01 Furosemide na na na 4.1 4.0 4.1
A10AD05 Insulin aspart na na na 3.5 4.2 3.9
S01ED01 Timolol 3.0 2.4 2.6 3.8 3.4 3.6
C10AA01 Simvastatin 1.8 1.4 1.6 3.6 2.8 3.1
C09AA06 Quinapril 3.0 3.5 3.3 3.0 3.2 3.1
A10BB09 Gliclazide 6.9 7.4 7.2 3.0 3.0 3.0
A10BB01 Glibenclamide na na na 2.3 3.0 2.8
C08CA05 Nifedipine 4.2 3.9 4.0 2.5 2.5 2.5
N05BA01 Diazepam 4.6 5.4 5.1 2.1 2.4 2.3
C09AA01 Captopril 18.6 19.7 19.3 2.1 2.2 2.2
R03AC02 Salbutamol, aerosol 5.5 1.9 3.3 3.3 1.5 2.2
M01AE01 Ibuprofen 2.8 3.4 3.2 1.3 1.5 1.4
ATC-code INN
2005 2010
 
NB: ATC - Anatomical Therapeutic Chemical; INN - International Non-proprietary Name; na - not 
applicable 
 
Discussion 
 
The study findings demonstrate increasing long-term medicine use among the elderly in the 
Republic of Srpska. Over a 5-year period, the proportion of the elderly who have used one 
medicine alone on a long-term basis declined; however, the proportion of patients who used 
multiple medicines increased (Table 2).  This increase in polypharmacy was observed in 
both men and women; however, the increase was more prominent in women of all age 
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groups. The use of multiple medicines and polypharmacy also increased with age. This is 
similar to the findings of Franchi et al who found that prescriptions for at least one chronic 
medicine increased from 73.8% of the elderly in 2000 to 82.5% in 2010 (34). However, 
these authors found that the prevalence of elderly taking only one medicine or two to four 
medicines decreased over time to 7.9% and 29.7% respectively; whilst those exposed to 
polypharmacy increased to 52.7% (34).  This is an appreciably higher prevalence of 
polypharmacy than seen in our study (Table 2). The different results in the prevalence of 
polypharmacy between studies could potentially be explained by differing inclusion criteria 
between the studies, variations in the duration of medicine use and the research period, data 
collecting methodologies and the representativeness of the study population. Although low, 
the prevalence of polypharmacy appreciably increased during the five year study period in 
the Republic of Srpska, with over half of all elderly patients taking 2 to 4 different 
medicines on a long-term basis for the treatment of chronic diseases by 2010 (Table 2).  
This needs to be addressed if prescribing is subsequently seen as inappropriate. 
 
Polypharmacy was slightly more prevalent in women than men and slightly more women 
were taking 2 to 4 medicines than men in 2010 (Table 2). This compares to similar rates for 
2 to 4 medicines in 2005 and marginally higher polypharmacy rates in men than women in 
2005 (Table 2). Many studies have reported a correlation between polypharmacy and 
female gender (26, 27, 31, 49), whilst a positive correlation between polypharmacy and 
men has been observed in only a limited number of studies (24, 50). Such discrepancies 
DPRQJVWXG\ILQGLQJVFRXOGEHGXHWRGLIIHUHQFHVLQSK\VLFLDQV¶SUHVFULbing attitude toward 
genders, as well as differences between genders in educational and socioeconomic 
characteristics (24). For instance, women consult health services more often and earlier 
than men, and are more accustomed to taking of medicines (51).  It is also known that those 
who report poor self-perceived health status are most likely to take medication (52), and in 
the Republic of Srpska in 2010 more women (20%) then men (16%) rated their health as 
worse than 12 months ago (53).  
 
Different reasons may have contributed to the observed increase in medicine use in the 
elderly in the Republic of Srpska in recent years (Table 2). Numerous new medicines and 
new dosage forms, mostly for the treatment of cardiovascular, metabolic, digestive, nervous 
and respiratory diseases, were included in the HIF list of reimbursable drugs during the 
observed period. Broader therapeutic options enabled better affordability and coverage of 
patients, particularly as a number of medicines were available in recent years that had 
previously not been reimbursed, i.e. 100% patient co-payment. Careful monitoring of 
medicines consumption combined with ongoing reforms enables the reimbursement of 
expensive targeted pharmaceuticals and other high-budget-impact medicines (54-56). 
 
Furthermore, there has been an aging of the population in the Republic of Srpska during the 
past two decades. Whilst the overall population decreased by 12% in the Republic of 
Srpska during the study period, the proportion of pHRSOHDJHGtripled, with people 
DJHGnow constituting 19% of the population (53, 57). Population aging is known as a 
major risk factor for development of chronic diseases and multiple medication use (51, 58).  
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Diabetes, heart disease, hypertension and obstructive pulmonary disease are well known 
relevant morbidity-related predictors of polypharmacy (26, 32). All of these conditions are 
prevalent among the elderly in the Republic of Srpska (Table 3). In fact, cardiovascular 
GLVHDVHVZHUHDOHDGLQJFDXVHRIPRUELGLW\DQGPRUWDOLW\LQWKH5HSXEOLFRI6USVND¶V
population in the last decade (59). 
 
As part of the national cardiovascular program to reduce morbidity and mortality, a 
particular focus was placed on the development of clinical guidelines (60) as well as the 
selection of cardiovascular medicines reimbursed by the HIF. This resulted in new diuretics 
(furosemide, torasemide, spironolactone, and combinations with amiloride), beta-blockers 
(metoprolol, bisoprolol), antiarrhythmics (amiodarone) and ACEIs (ramipril, trandolapril) 
being included in the list of reimbursed drugs in 2010. These new clinical guidelines 
DSSHDUHGWRLQIOXHQFHSK\VLFLDQV¶SUHVFULELQJSDWWHUQV, with these guidelines often 
recommending prescribing of several medicines to treat or prevent diseases (60-62).     
Alongside this, older patients often have multiple co-morbidities leading to an increasing 
number of different medicines prescribed (Tables 3 and 4), which is seen in other studies 
(63). This could itself lead to relatively high prescribing of ranitidine amongst the elderly to 
potentially prevent GI side-effects or as prophylactic therapy in multiple drug use 
³SUHVFULELQJFDVFDGH´to reduce GERD (gastroesophageal reflux disorders)  (Table 4). 
However, we cannot confirm this statement with certainty without specific research in this 
area. For example when choosing medicines to treat hypertension alone or in combination, 
among the five main classes of antihypertensive medicines (thiazide diuretics, beta-
blockers, ACEIs, CCBs, and angiotensin receptor blockers - ARBs), the  official national 
guidelines recommend taking into account any comorbidities patients may have, treatments 
that can be taken only once a day, and their price. Besides hypertension, three more CV 
diseases were among the top diseases of the elderly for which medicines were prescribed 
along with diabetes type 2 (Table 3).  
 
Overall, ACEIs alone or in combination with other drugs were the most prescribed 
medicines in the Republic of Srpska for this population (Table 4). This is perhaps not 
surprising since, as mentioned, cardiovascular diseases were a leading cause of morbidity 
DQGPRUWDOLW\LQWKH5HSXEOLFRI6USVND¶VSRSXODWLRQLQWKHODVWGHFDGH(59) and 
hypertension was seen among 77% of the elderly population on long-term medicines in 
2010 (Table 3). ACEIs have outcome advantages for patients with concomitant 
cardiovascular diseases, heart failure and diabetes including benefits to prevent 
nephropathy (64-66). In addition, where monotherapy is inadequate for controlling BP and 
preventing cardiovascular disease outcomes and stroke in the elderly, ACEIs are effective 
in combination with a diuretic. The guideline recommendations and the prevalence of CV 
disease in the Republic of Srpska, coupled with knowledge of therapeutics, probably led to 
the increased prescribing of ACEIs, alone and combination with hydrochlorothiazide, in 
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recent years, adding to earlier and more consistent treatment of patients with CV disease 
(Table 4). A high proportion of patients prescribed fixed-dosage combinations of ACEI 
with hydrochlorothiazide may be due to the guidelines indicating a strong preference for 
thiazide diuretics when combination therapies are needed, often for high risk patients (60, 
67). In addition, lower doses may be used resulting in fewer side-effects and better 
compliance and adherence to prescribed antihypertensive medicines. Alongside this 
prescribing of captopril decreased (Table 4), helped no doubt by the broader availability of 
medicines dosed once-daily, e.g. enalapril, and a higher patient copayment (50%). 
  
CCBs are also among the preferred medicines to treat hypertension in the elderly, and 
amlodipine was widely prescribed (Table 4). Amlodipine is seen as safe for use in patients 
with heart failure, hypertension, chronic stable angina and diabetes (68), which were all 
prevalent in the elderly in this study (Table 3). Among available beta-blockers, carvedilol is 
probably more widely prescribed to treat patients with cardiovascular disease with 
metabolic syndrome or diabetes as it affects insulin sensitivity less than metoprolol (61), 
and cardioselective metoprolol has a preferable side effect profile in older persons and a 
lower price than bisoprolol. These considerations probably resulted in the appreciable use 
of carvedilol and metoprolol in this study (Tables 3 and 4).  
 
Guidelines for the management of dyslipidaemia in the Republic of Srpska recommend the 
prescribing of statins as safe and effective in patients who either already have 
cardiovascular disease, e.g. patients following a heart attack or stroke (61, 62), or patients 
who are at risk of developing cardiovascular disease as  well, e.g. diabetic patients with 
distinct metabolic disorders alongside other pathophysiologies (60). This probably 
contributed to increasing use of statins in recent years (Table 4), augmented by the 
increasing prevalence of patients with diabetes (Table 3).  
 
Current guidelines for patients with diabetes in the Republic of Srpska recommend early 
initiation of metformin as a first-line drug treatment for monotherapy, and combination 
therapy for patients with type 2 diabetes (61). Sulfonylureas are a second choice in patients 
with contraindications and/or intolerance to metformin. This recommendation was based 
SULPDULO\RQPHWIRUPLQ¶VJOXFRVH-lowering effects, relatively low cost, and generally low 
level of side effects (61). As a result, more than doubling the prescribing of metformin in 
recent years (Table 4) enhanced by, as stated, the increasing prevalence of patients with 
Type 2 diabetes (Table 3).   
 
Alongside this, there has been reduced prescribing of some older medicines, e.g. ranitidine, 
gliclazide, nifedipine, ibuprofen, diazepam and captopril (Table 4) during the past five 
years. We believe this is as a direct consequence of the introduction of the new clinical 
guidelines into clinical practice in the Republic of Srpska.  
 
A concern though is the continued high use of digoxin (Table 4), as it has a narrow 
therapeutic margin as well as frequent and potentially severe adverse effects (69). As a 
result, guidelines in the Republic of Srpska recommend that digoxin should not be 
prescribed as a first-line treatment for heart failure (70). Generally, digoxin should be 
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reserved for worsening or severe heart failure not responding to first-and second-line 
treatments (71). However, it remains a useful treatment option for heart failure associated 
with atrial fibrillation. The findings also showed that aminophylline is still frequently 
prescribed for treatment of chronic obstructive pulmonary disease (COPD) although rates 
are decreasing (Tables 3 and 4). This again was quite unexpected since in the guidelines for 
treating COPD, theophylline and its derivate aminophylline are traditionally relegated to a 
WKLUGOLQHEURQFKRGLODWRUDIWHULQKDOHGDQWLFKROLQHUJLFVDQGȕ2-agonists (72). Its use as a 
first-line bronchodilator being replaced by safer and more potent preparations, particularly 
in elderly who have different pharmacokinetic profiles and greater risk of developing side 
effects to theophylline (73).  Consequently, it is intended that there will be educational 
initiatives in the Republic of Srpska to address both anomalies.  
 
One conclusion from our findings (Tables 3 and 4) is that an appreciable proportion of 
patients in the Republic of Srpska are being prescribed recommended medicines in line 
with the new guidelines. However, we acknowledge further research is needed to clarify 
this before more definitive conclusions can be drawn. One reason for this hypothesis is that 
similar to other studies (47, 51), the elderly population in the Republic of Srpska mostly 
took medicines for cardiovascular, alimentary tract and metabolism and respiratory system 
diseases (Tables 3 and 4). These similarities in consumption patterns may reflect common 
therapeutic needs among elderly patients, and applying a standard prescription scheme 
regarding patients¶ ages (74).  
 
We believe the major advantage of this study is the large and reliable data set analyzed, 
FRYHULQJDOOUHLPEXUVHGSUHVFULSWLRQVWRHYHU\LQGLYLGXDODJHG in the Republic of 
Srpska. This is the only comprehensive and consistent database of outpatient prescriptions 
in the Republic of Srpska, ensuring robustness with the findings. However, we 
acknowledge that the use of medicines in our population may have been underestimated as 
the HIF database does not include prescription medicines not reimbursed by the HIF as well 
as non-prescription medicines, e.g. OTC medicines. In addition, we do not know whether 
all analyzed medicines were actually taken by patients. However, we believe our findings 
are still valid and provide a base case for assessing future initiatives in the Republic of 
Srpska. 
 
In conclusion, the study findings point to an increase in the elderly population with long-
term medicine use. Whilst the prevalence of polypharmacy in the Republic of Srpska 
appears low compared with other studies, it has increased. This may well be due to the 
increasing prevalence of chronic diseases among the elderly alongside the ageing of the 
population, instigation of clinical guidelines for chronic diseases in the Republic as well as 
more medicines being available on the reimbursement lists to treat chronic conditions, 
especially CV diseases. However, there were concerns with high use of digoxin and 
theophylline (Table 4). Future research activities are planned to enhance knowledge about 
prescribing in this population to confirm or not the generally positive findings and the 
tentative explanations. This includes possible drug interactions among the elderly, greater 
monitoring of medicine use among the elderly, as well as monitoring adherence to current 
guidelines. 
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Alongside this, educational activities among physicians regarding the prescribing of 
digoxin in patients with heart failure and theophylline for COPD. The possibility for 
including other measures to address potentially inappropriate prescribing using for instance 
measures introduced in Croatia, Slovenia and Serbia will also be explored in future studies, 
building on recent research (75-77).  
 
Five year view 
 
It is anticipated that the rates of polypharmacy will grow in the Republic of Srpska over the 
coming five years with an ageing population and greater prevalence of patients with 
chronic diseases. Alongside this, educational interventions along with other measures to 
improve the appropriateness of prescribing and reduce inappropriate prescribing including 
digoxin and aminophylline.  This could include measures used in other Balkan countries as 
well as across Europe and other continents. As a result, help to improve the care of the 
elderly in the Republic of Srpska within limited resources.  
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Key points 
 
x The prevalence of polypharmacy in the Republic of Srpska is currently low but 
increasing  
x This increase is similar across countries where there is also an increase in the number of 
patients prescribed medicines long-term, as well as increased prevalence of patients 
prescribed two to four different medicines. Alongside this, there is a fall in the number 
of elderly taking one medicine alone long term 
x Polypharmacy is most prominent in the age group 85 and older 
x Women take more different medicines across all age groups than men; however, this 
was not universal. One medicine alone was taken by more men of all age groups   
x Cardiovascular diseases including hypertension, angina, and ischaemic heart disease as 
well as heart failure are among the most prevalent conditions in the elderly along with 
diabetes (Types 1 and 2) and chronic bronchitis/ other forms of chronic obstructive 
pulmonary disease 
x Medicines prescribing in the Republic of Srpska appears typically based on national 
guideline criteria. This is illustrated by reduced prescribing of a number of older 
medicines as a consequence of the new guidelines, e.g. gliclazide, nifedipine, captopril, 
ibuprofen, diazepam 
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